证券之星消息，1月22日医疗美容板块较上一交易日下跌1.35%，锦波生物领跌。当日上证指数报收于 4122.58，上涨0.14%。深证成指报收于14327.05，上涨0.5%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 000615 | *ST美谷 | 3.34 | 1.52% | 6.09万 | 2015.48万 | | 688363 | 华熙生物 | 45.54 | -0.76% | 2.88万 | 1.32 Z | | 300896 | 爱美客 | 141.60 | -2.07% | 3.12万 | 4.46 乙 | | 920982 | 锦波生物 | 226.99 | -2.21% | 7993.54 | 1.83亿 | | 代码 | 名称 | | | 主力净流入（元） 主力净占比 游资净流入（元） 游资净占比 散户净流入 (元) 散户净占比 | | | | | --- | --- | --- | --- | --- | --- | --- | --- ...

近期，曾凭借"玻尿酸龙头"光环市值破千亿的华熙生物，正陷入一场资本与业绩的双重考验。股东频繁 减持、业绩连续下滑、市值大幅缩水，这家曾经的行业明星企业，正试图通过"断腕"式调整寻找生机。 然而，走出低谷的道路依然布满荆棘。 一、股东密集减持，资本"用脚投票" 自2024年10月起，华熙生物第二大股东国寿成达频繁减持公司股份，持股比例从7.15%一路降至 4.01%。截至2025年1月，其通过两次大规模减持累计套现约7.69亿元。如此集中且巨额的减持行为，被 市场视为强烈的资本"离场"信号，反映出机构投资者对公司短期前景的谨慎态度。 股东减持往往不是孤立行为，其背后通常隐含着对公司成长性、行业竞争力或治理结构的隐忧。在业绩 承压的背景下，大股东减持进一步动摇了市场信心，加剧了股价下行压力。截至最近收盘，华熙生物总 市值已萎缩至约222亿元，与千亿巅峰相距甚远。 二、业绩持续探底，"瘦身"能否换来"强身"？ 财务数据显示，华熙生物的营收与净利润已进入下行通道。2024年营收同比下降11.61%，归母净利润 暴跌70.59%；2025年前三季度营收继续下滑18.36%，净利润同比下降30.29%。尽管2025年第二 ...

值得关注的是，华熙生物中试转化平台以 "行业级基础设施" 定位向全社会开放，通过成果转让、合作 开发、委托中试等模式，为高校、科研院所、初创企业提供全链条中试转化服务，推动"政产学研金服 用"深度融合。 此次五星认证的落地，是国家加速生物制造产业布局的重要信号。2025年6月，工信部与国家发改委联 合发文，明确到2027年培育20个以上生物制造中试平台。作为第四次工业革命的重要标志，生物制造已 成为全球产业竞争焦点，预计2030年全球市场规模将突破3900亿美元。华熙生物表示，未来将持续发挥 平台枢纽作用，助力我国生物制造产业在全球竞争中抢占先机。 关键词阅读：华熙生物责任编辑：栎树 近期，工业和信息化部首批《生物制造中试能力建设平台名单》公示收官，华熙生物科技（天津）有限 公司凭借全球规模领先的合成生物中试平台成功入选，并获最高"五星"等级认证。该企业成为全国仅有 的5家五星单位之一，且在化妆品、食品添加剂、生物制药三大核心领域同时拿下最高认证，标志着我 国生物制造领域中试基础设施建设取得关键突破。 中试平台是破解生物制造科研成果转化"死亡之谷"的核心枢纽。数据显示，我国科技成果转化率仅约 10%，远低于欧 ...

Market Overview - The medical beauty sector experienced a decline of 1.35% on January 20, with *ST Meigu leading the drop [1] - The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1] Stock Performance - Key stocks in the medical beauty sector showed the following performance: - Huaxi Biological (688363) closed at 45.82, down 0.82% with a trading volume of 35,000 shares and a turnover of 161 million yuan [1] - Aimeike (300896) closed at 144.82, down 1.59% with a trading volume of 30,000 shares and a turnover of 436 million yuan [1] - Jinbo Biological (920982) closed at 234.11, down 1.96% with a trading volume of 6,327 shares and a turnover of 149 million yuan [1] - *ST Meigu (000615) closed at 3.24, down 2.70% with a trading volume of 106,900 shares and a turnover of 34.95 million yuan [1] Capital Flow - The medical beauty sector saw a net outflow of 100 million yuan from main funds, while retail investors contributed a net inflow of 74.88 million yuan [1] - Detailed capital flow for key stocks includes: - *ST Meigu: Main funds net outflow of 11.12 million yuan, retail net inflow of 6.93 million yuan [2] - Jinbo Biological: Main funds net outflow of 25.90 million yuan, retail net outflow of 1.30 million yuan [2] - Huaxi Biological: Main funds net outflow of 31.89 million yuan, retail net inflow of 22.38 million yuan [2] - Aimeike: Main funds net outflow of 57.26 million yuan, retail net inflow of 45.57 million yuan [2]

Core Insights - The article emphasizes the rising importance of biomanufacturing as a strategic and innovative sector, which is seen as a new growth point that can help optimize industrial structures and transform economic models [1]. Group 1: Current State and Trends - The "2025 China Synthetic Biomanufacturing Industry Development White Paper" was officially released on August 1, highlighting the current status and trends in biomanufacturing [1]. - The report analyzes the global biomanufacturing industry, including key platform facilities and a comparative study of the US and China in this field [5]. Group 2: Policy Landscape - The white paper discusses major policies affecting biomanufacturing both domestically and internationally for the years 2024-2025 [5]. Group 3: Industry Map and Applications - It provides a comprehensive map of the Chinese biomanufacturing industry and analyzes the industry chain along with key application directions, including biomanufacturing in pharmaceuticals, food, personal care, agriculture, chemicals, materials, and energy [5]. Group 4: Key Enterprises - The report identifies ten leading enterprises in the Chinese biomanufacturing sector, detailing their contributions and roles within the industry [5][6]. Group 5: Company Strategies - It outlines the synthetic biology strategies of 15 listed companies, summarizing their development approaches and corresponding popular products [5][6]. Group 6: Investment and Challenges - The white paper reviews the investment and financing situation in domestic synthetic biology from 2024 to mid-2025 and discusses the challenges faced by the biomanufacturing industry in China, along with proposed countermeasures [5][6].

Group 1 - The medical beauty sector increased by 0.06% on January 19, with Jinbo Biological leading the gains [1] - The Shanghai Composite Index closed at 4114.0, up 0.29%, while the Shenzhen Component Index closed at 14294.05, up 0.09% [1] - Jinbo Biological's closing price was 238.79, with a rise of 1.61%, while other companies like Aimeike and Huaxi Biological showed mixed performance [1] Group 2 - The medical beauty sector experienced a net outflow of 808.89 million yuan from main funds, while retail investors saw a net inflow of 5.19 million yuan [1] - Aimeike had a main fund net inflow of 16.01 million yuan, but also faced significant outflows from retail and speculative funds [2] - Jinbo Biological saw a main fund net inflow of 10.08 million yuan, with a notable retail net inflow of 4.28 million yuan [2]

Core Insights - The announcement of the first batch of "Biomanufacturing Pilot Capability Construction Platform List" by the Ministry of Industry and Information Technology highlights Huaxi Biological Technology (Tianjin) Co., Ltd. as a leading player, achieving the highest "five-star" rating and being one of only five such units in the country [1] - The recognition emphasizes the importance of pilot platforms in bridging the gap between research and industrialization in biomanufacturing, addressing the low technology transfer rate in China compared to developed countries [1][2] Group 1: Company Achievements - Huaxi Biological has invested over 3 billion yuan to create the world's largest synthetic biology pilot transformation platform, featuring 64 pilot production lines across a 40,000 square meter facility [2] - The platform supports the scale-up of six categories of bioactive substances, serving multiple strategic emerging industries including pharmaceuticals, cosmetics, and functional foods [2][3] Group 2: Industry Context - The pilot platform is crucial for overcoming the challenges of scaling up from laboratory to industrial production, addressing issues such as process optimization, quality control, and cost accounting [2] - The Chinese government aims to cultivate over 20 biomanufacturing pilot platforms by 2027, recognizing biomanufacturing as a key aspect of the Fourth Industrial Revolution, with a projected global market size exceeding $390 billion by 2030 [3][4] Group 3: Collaborative Efforts - The pilot transformation platform is designed to be an industry-level infrastructure, providing comprehensive services to universities and startups, thus promoting the integration of government, industry, academia, research, finance, and application [4] - Huaxi Biological aims to enhance the overall capabilities of China's biomanufacturing sector through collaboration and the development of a robust platform ecosystem [4]

Investment Rating - Investment rating: Positive (maintained) [1] Core Insights - The luxury goods retail revenue in China is showing signs of recovery, with high-end brands like LVMH, Hermès, and Prada experiencing positive growth since Q2 2025 [15][16] - The global network literature market is witnessing rapid growth, particularly in Latin America, with WebNovel reaching nearly 400 million cumulative users by October 2025 [34][35] - The micro-drama and comic-drama market in China is projected to exceed 100 billion yuan in 2025, significantly surpassing the film box office revenue [37][38] - The probiotic market is expanding, with a focus on next-generation probiotics (NGPs) like AKK bacteria, which show significant potential in health applications [55][63] Summary by Sections 1. Duty-Free Shopping - Post-New Year duty-free shopping in Hainan shows strong growth, with sales reaching 3.89 billion yuan and a 49.6% year-on-year increase in shopping amount [31][33] - The high net worth individuals are expected to drive luxury consumption, with a notable increase in spending on preservation-type luxury goods [15][16] 2. Network Literature - The Chinese network literature market reached 49.55 billion yuan in 2024, with a 29.37% year-on-year growth, while the overseas market grew by 10.68% [34] - WebNovel has cultivated nearly 530,000 authors and over 820,000 original works, with a significant increase in user engagement [34][35] 3. Micro-Drama - The micro-drama and comic-drama market in China is expected to reach 100 billion yuan in 2025, with a 98% year-on-year growth [37][38] - The user base for micro-dramas is approaching 700 million, with a strong preference among female viewers [40][42] 4. Probiotics - The global probiotic market is projected to grow at a CAGR of 8.7%, reaching 93.49 billion USD by 2028, with China's market expected to reach 134.89 billion yuan by 2024 [55][63] - Next-generation probiotics like AKK bacteria are gaining traction, with significant potential in health management and consumer interest [55][63]

Group 1 - The major shareholder, Guoshou Chengda, held 28,936,504 shares of Huaxi Biological Technology Co., Ltd., accounting for 6.01% of the total share capital before the reduction plan [2] - The reduction plan involved a maximum of 9,633,564 shares, representing up to 2.00% of the total share capital, with a maximum of 4,816,782 shares to be reduced through both centralized bidding and block trading [3] - As of January 15, 2026, Guoshou Chengda completed the reduction of 9,633,564 shares, with 4,816,782 shares reduced through centralized bidding and 4,816,782 shares through block trading [3][5] Group 2 - The reduction plan was disclosed on November 5, 2025, and the reduction period was set from November 26, 2025, to February 23, 2026 [3] - The actual reduction adhered to relevant laws and regulations, and there were no violations of the reduction plan or other commitments [6]

证券代码：688363 证券简称：华熙生物 公告编号：2026-002 华熙生物科技股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持有的基本情况 本次减持计划实施前，国寿成达（上海）健康产业股权投资中心（有限合伙） （以下简称"国寿成达"）直接持有华熙生物科技股份有限公司（以下简称"公司"） 股份数量为 28,936,504 股，占公司总股本的 6.01%。上述股份全部为公司首次公 开发行前股份，并已于 2022 年 11 月 7 日起上市流通。 减持计划的实施结果情况 公司于 2025 年 11 月 5 日在上海证券交易所网站（www.sse.com.cn）披露《华 熙生物科技股份有限公司股东减持股份计划公告》（公告编号：2025-043），国寿 成达计划根据市场情况通过集中竞价、大宗交易的方式减持其所持有的公司股份 合计不超过 9,633,564 股，拟减持股份数量占公司总股本的比例合计不超过 2.00%， 其中以集中竞价方式减持比例不超过 1.0 ...